IL-15 superagonist

0 marketed 1 in Phase 3 1 in Phase 2

This page covers all IL-15 superagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-15 receptor (IL-15R), IL-15 receptor complex.

Targets

IL-15 receptor (IL-15R) · IL-15 receptor complex

Phase 3 pipeline (1)

N-803 · National Cancer Institute (NCI) · Oncology
N-803 is a superagonist of the IL-15 receptor that expands and activates natural killer cells and CD8+ T cells to enhance anti-tumor immunity.

Phase 2 pipeline (1)

ALT-803 · ImmunityBio, Inc. · Oncology
ALT-803 is an IL-15 superagonist that stimulates the expansion of natural killer cells and CD8+ T cells.